AI Article Synopsis
- The study aimed to assess how adjuvant letrozole affects the rate of euploid embryos in patients undergoing GnRH antagonist cycles for fertility treatments.
- It analyzed data from 713 patients, comparing 84 who received letrozole with 629 who did not, noting that those on letrozole used fewer gonadotropins but had a slightly longer stimulation time.
- The results showed no significant difference in euploidy rates or live birth rates between the letrozole and control groups, concluding that letrozole does not impact embryo quality in this context.
Article Abstract
Objective: To evaluate the effects of adjuvant letrozole administration on euploid embryo rates in gonadotropin releasing hormone (GnRH) antagonist cycles.
Methods: This retrospective study was conducted by analyzing data of patients that underwent GnRH antagonist cycles with intra-cytoplasmic sperm injection (ICSI) and pre-implantation genetic testing for aneuploidy between 2013 and 2021. Study included a total of 713 patients which 84 of them were received adjuvant letrozole and 629 patients underwent ovulation induction without any adjuvant therapy.
Results: In patients with letrozole administration, total dose of consumed gonadotropins were significantly lower (2166.80±738.82 IU vs. 2541.96±755.76 IU; p<0.001, respectively), and duration of stimulation was slightly longer (9.80±1.23 days vs. 9.53±1.38 days; p=0.037) in comparison to patients without letrozole administration. Overall euploidy rates were found similar among letrozole group and control group (28.02%±31.08% vs. 23.02%±30.87%; p=0.109). Similar rate of euploidy remained even after stratification of patients in accordance with female age. There was no significant difference in terms of live birth rates between letrozole administered group and control group (66.7% vs 62.2%, respectively).
Conclusion: Co-treatment with 5 mg/day letrozole for 5 days does not appear to affect euploidy rates of obtained embryos in GnRH antagonist cycles with ICSI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jogoh.2023.102689 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Infertility is a significant health problem with psycho-social burden for couples. Ayurveda considers a holistic approach, including complex multimodal regimens in managing infertility. Increasing evidence has shown that Yoga as an adjuvant to infertility treatment increases pregnancy rates.
View Article and Find Full Text PDFSynchronous Primary Metastatic Infra-Mammary Accessory Breast Cancer and Ipsilateral Breast Cancer: An Extremely Rare Case Report.
Diagnostics (Basel)
November 2024
Clinic of Surgical Semiotics and Thoracic Surgery-1, Department IX-Surgery-1, "Victor Babes" University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Accessory breast cancer cases are rarely reported in the literature. Of the reported cases, the predominantly available ones are those localized in the axillary region. We present here a very rare case of metastatic accessory breast cancer.
View Article and Find Full Text PDFSelection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial.
JAMA Netw Open
November 2024
Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Article Synopsis
- In early-stage breast cancer (EBC) patients, there is a need for biomarkers to predict the risk of late recurrence and the benefit from extended endocrine therapy (EET), specifically using the MammaPrint 70-gene assay to identify low-risk tumors.
- The study analyzed postmenopausal women with hormone receptor-positive EBC from the IDEAL trial to see if the MammaPrint assay could help decide between 2.5 years and 5 years of treatment with letrozole.
- Results showed that patients with low-risk tumors had a significant benefit of 10.1% for distant recurrence with longer treatment, while no significant benefits were found for high-risk or ultralow risk patients regarding treatment duration
Chronic Aromatase Inhibition Attenuates Synaptic Plasticity in Ovariectomized Mice.
eNeuro
November 2024
Solomon H. Snyder Department of Neuroscience, Johns Hopkins University, Baltimore, Maryland 21210
Brain-derived estrogen (17β-estradiol, E2) is a neuromodulator that plays important roles in neural plasticity and network excitability. Chronic inhibition of estrogen synthesis is used in adjuvant breast cancer therapy for estrogen receptor-positive tumors and may have been associated with cognitive and affective side effects. Here, we have developed a model of adjuvant therapy in female ovariectomized mice in which the E2 biosynthetic enzyme aromatase is inhibited by letrozole (1 mg/kg/day, i.
View Article and Find Full Text PDFAdjuvant letrozole administration in gonadotropin releasing hormone antagonist cycles do not affect ploidy status of embryos.
J Gynecol Obstet Hum Reprod
October 2023
Acibadem Atasehir Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey.
Article Synopsis
- The study aimed to assess how adjuvant letrozole affects the rate of euploid embryos in patients undergoing GnRH antagonist cycles for fertility treatments.
- It analyzed data from 713 patients, comparing 84 who received letrozole with 629 who did not, noting that those on letrozole used fewer gonadotropins but had a slightly longer stimulation time.
- The results showed no significant difference in euploidy rates or live birth rates between the letrozole and control groups, concluding that letrozole does not impact embryo quality in this context.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!